XenoPort, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1999-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://xenoport.com
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT00557401
- Locations
- 🇺🇸
MDS Pharma Services, Irvine, California, United States
A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00557973
XP13512 vs. Placebo in Patients With Restless Legs Syndrome.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT00365352
XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 581
- Registration Number
- NCT00333359
Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 327
- Registration Number
- NCT00311363
XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-03-02
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT00298623
© Copyright 2024. All Rights Reserved by MedPath